Producing an effective vaccine for malaria is a difficult task because Plasmodium — the parasite that transmits the disease — has a protein that hinders the creation of memory T-cells. The human body must be able to create these T-cells, which protect against future infections, for vaccines to work.
The new vaccine uses RNA technology to bypass the protein, thus allowing for the creation of T-cells. The vaccine has not been tested in humans but achieved “probably the highest level of protection that has been seen in a mouse model,” Richard Bucala, MD, PhD, the vaccine’s co-inventor and a professor of medicine, pathology, and epidemiology at the Yale School of Medicine, told The Academic Times.
In 2019, malaria sickened an estimated 229 people globally and killed 409,000. At present, the only FDA-approved vaccine on the market is 30 percent effective for the first four years after inoculation.
The researchers filed the patent application Feb. 4. Their work was funded by Novartis Pharmaceuticals and the National Institutes of Health.
To learn more, click here.
More articles on public health:
COVID-19 hospitalizations by state
States ranked by percentage of COVID-19 vaccines administered
Daily COVID-19 case average down 73% from winter peak: 11 CDC stats to know
